With CURE TV®, you have access to a variety of informative and uplifting videos. You’ll find interviews with cancer experts, advocates, patients, caregivers, as well as highlights from our celebratory events showcasing interviews with award winners and celebrity speakers.
February 26th 2020
Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.
February 25th 2020
Here’s a look at what’s inside our 2020 Winter issue.
February 24th 2020
Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.
February 24th 2020
The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.
February 21st 2020
A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.
February 20th 2020
The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
February 4th 2020
The incidence of colorectal and gastric cancers has risen for younger patients, and many of them share ethnic and socioeconomic disparities as well.
February 2nd 2020
Take a look back at the top five CURE® stories for January 2020.
February 1st 2020
A subset of patients with metastatic pancreatic cancer and an inherited BRCA mutation rapidly progressed during a clinical trial of Lynparza.
January 31st 2020
A circulating cell-free DNA test for patients with gastrointestinal cancers has a 90% accuracy rate to detect patients’ cancers and could provide a standard test in the future, according to new study findings.
January 30th 2020
The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.
January 29th 2020
The cancer landscape has changed for patients with the introduction of targeted therapies, and a combination targeted therapy for some patients with colorectal cancer shows new promise.
January 24th 2020
The expert who created an assessment tool to help patients with myeloproliferative neoplasms explain their symptoms to their care ream shares how the idea came to fruition.
January 23rd 2020
Kurt Schroeder, a research nurse, pushes for a patient-first mentality, especially as they participate in a clinical trial.
January 22nd 2020
Ann McMullin fought for her son to be properly diagnosed and is advocating for more education among medical professionals of rare diseases like her son’s essential thrombocythemia.
January 20th 2020
As a guest speaker at the 2019 MPN Heroes ® Recognition Ceremony, Dr. David C. Fajenbaum had the chance to discuss how translational research is a vital part of getting the right treatment to patients with cancer.
January 18th 2020
Because they have been found to be effective in the treatment of many types of cancer, including melanoma, immunotherapy drugs like anti-PD-1 agents and anti-CTLA4 therapies should not be discounted because of their toxicities.
January 17th 2020
Emergency room visits are costly and take a lot of time patients with cancer don’t have, which is why the creation of a 24-hour clinic to address cancer related symptoms and treatment side effects could prove vital for patients.
January 14th 2020
Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.
January 14th 2020
For Natalie Catalano, caregiving for her daughter with essential thrombocythemia included not only being a rock of support, but also being a vocal advocate for her daughter’s care team to make the right diagnosis.
January 11th 2020
Madeleine Henriquez noticed that the mental health care of patients with MPN was being overlooked and took action in a way that has changed her community for the better.
January 8th 2020
Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.
January 6th 2020
Patients with rare blood cancers are not all the same, and this understanding has helped Dr. Irum Khan become an advocate for people with these conditions — and an MPN Hero.
January 5th 2020
Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.
December 26th 2019
Young women and women of color with breast cancer, as well as those with metastatic disease, had the chance to experience SABCS 2019 and advocate for representation of their patient groups in ongoing clinical trials.
December 25th 2019
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
December 22nd 2019
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
December 20th 2019
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
December 19th 2019
New findings show that Ibrance has the potential to help patients with brain metastases that harbor a CDK pathway alteration.